Halozyme Therapeutics stock hits all-time high of 104.86 USD
Halozyme Therapeutics Inc stock surged to an all-time high of $104.86, signaling substantial growth for the company. Currently trading at $104.93 with a market cap of $11.88 billion, the stock trades near its InvestingPro Fair Value. Over the past year, the stock soared 49.33%, with a year-to-date return of 53% and a six-month gain of 41%.
Three analysts have upgraded their earnings forecasts for Halozyme, one of 16 valuable insights for subscribers. This surge reflects robust investor confidence in the company's performance and future outlook. Halozyme's latest quarter results beat expectations, reporting non-GAAP earnings of $2.28 per share against the estimated $1.81.
Revenue reached $481 million, surpassing the anticipated $401.27 million, fueled by record royalty revenue and strong growth in partnered drugs. This has led to an upward revision of the company's full-year outlook by investors. Additionally, price targets for Halozyme have been raised, with Citizens setting it at $93 and H.C. Wainwright maintaining a Buy rating with a target of $115, citing promising Phase 3 trial results from Argenx's VYVGART Hytrulo trial.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
